Factors associated with concomitant psychotropic drug use in the treatment of major depression: A STAR*D report

Richard C. Shelton, Steve D. Hollon, Stephen R. Wisniewski, Jonathan E. Alpert, G. K. Balasubramani, Edward S. Friedman, A. John Rush, Madhukar H. Trivedi, Sheldon H. Preskorn

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Concomitant psychotropic medication (CPM) treatment is common in persons with major depression (MDD). However, relationships with patient characteristics and response to treatment are unclear. Methods: Participants with nonpsychotic MDD (N=2682) were treated with citalopram, 20-60 mg/day. Sociodemographic, clinical, and treatment outcome characteristics were compared between those using CPMs at study entry or during up to 14 weeks of citalopram treatment, and non-users. Results: About 35% of participants used a CPM. Insomnia was the predominant indication (70.3%). CPM users were more likely to be seen in primary care settings (69.3% versus 30.7%), be white, of non-Hispanic ethnicity, married, and have a higher income, private insurance, and certain comorbid disorders. CPM users had greater depressive severity, poorer physical and mental functioning, and poorer quality of life than non-users. Response and remission rates were also lower. CPM users were more likely to achieve ≥50 mg/day of citalopram, to report greater side effect intensity, and to have serious adverse events, but less likely to be intolerant of citalopram. Conclusion: CPMs are associated with greater illness burden, more Axis I comorbidities (especially anxiety disorders), and lower treatment effectiveness. This suggests that CPM use may identify a more difficult to treat population that needs more aggressive treatment.

Original languageEnglish (US)
Pages (from-to)487-498
Number of pages12
JournalCNS Spectrums
Volume14
Issue number9
StatePublished - 2009
Externally publishedYes

Fingerprint

Citalopram
Psychotropic Drugs
Depression
Cost of Illness
Sleep Initiation and Maintenance Disorders
Therapeutics
Insurance
Anxiety Disorders
Comorbidity
Primary Health Care
Quality of Life
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Shelton, R. C., Hollon, S. D., Wisniewski, S. R., Alpert, J. E., Balasubramani, G. K., Friedman, E. S., ... Preskorn, S. H. (2009). Factors associated with concomitant psychotropic drug use in the treatment of major depression: A STAR*D report. CNS Spectrums, 14(9), 487-498.

Factors associated with concomitant psychotropic drug use in the treatment of major depression : A STAR*D report. / Shelton, Richard C.; Hollon, Steve D.; Wisniewski, Stephen R.; Alpert, Jonathan E.; Balasubramani, G. K.; Friedman, Edward S.; Rush, A. John; Trivedi, Madhukar H.; Preskorn, Sheldon H.

In: CNS Spectrums, Vol. 14, No. 9, 2009, p. 487-498.

Research output: Contribution to journalArticle

Shelton, RC, Hollon, SD, Wisniewski, SR, Alpert, JE, Balasubramani, GK, Friedman, ES, Rush, AJ, Trivedi, MH & Preskorn, SH 2009, 'Factors associated with concomitant psychotropic drug use in the treatment of major depression: A STAR*D report', CNS Spectrums, vol. 14, no. 9, pp. 487-498.
Shelton RC, Hollon SD, Wisniewski SR, Alpert JE, Balasubramani GK, Friedman ES et al. Factors associated with concomitant psychotropic drug use in the treatment of major depression: A STAR*D report. CNS Spectrums. 2009;14(9):487-498.
Shelton, Richard C. ; Hollon, Steve D. ; Wisniewski, Stephen R. ; Alpert, Jonathan E. ; Balasubramani, G. K. ; Friedman, Edward S. ; Rush, A. John ; Trivedi, Madhukar H. ; Preskorn, Sheldon H. / Factors associated with concomitant psychotropic drug use in the treatment of major depression : A STAR*D report. In: CNS Spectrums. 2009 ; Vol. 14, No. 9. pp. 487-498.
@article{b0250c913dc243c0b4192a1ee74b2ff6,
title = "Factors associated with concomitant psychotropic drug use in the treatment of major depression: A STAR*D report",
abstract = "Introduction: Concomitant psychotropic medication (CPM) treatment is common in persons with major depression (MDD). However, relationships with patient characteristics and response to treatment are unclear. Methods: Participants with nonpsychotic MDD (N=2682) were treated with citalopram, 20-60 mg/day. Sociodemographic, clinical, and treatment outcome characteristics were compared between those using CPMs at study entry or during up to 14 weeks of citalopram treatment, and non-users. Results: About 35{\%} of participants used a CPM. Insomnia was the predominant indication (70.3{\%}). CPM users were more likely to be seen in primary care settings (69.3{\%} versus 30.7{\%}), be white, of non-Hispanic ethnicity, married, and have a higher income, private insurance, and certain comorbid disorders. CPM users had greater depressive severity, poorer physical and mental functioning, and poorer quality of life than non-users. Response and remission rates were also lower. CPM users were more likely to achieve ≥50 mg/day of citalopram, to report greater side effect intensity, and to have serious adverse events, but less likely to be intolerant of citalopram. Conclusion: CPMs are associated with greater illness burden, more Axis I comorbidities (especially anxiety disorders), and lower treatment effectiveness. This suggests that CPM use may identify a more difficult to treat population that needs more aggressive treatment.",
author = "Shelton, {Richard C.} and Hollon, {Steve D.} and Wisniewski, {Stephen R.} and Alpert, {Jonathan E.} and Balasubramani, {G. K.} and Friedman, {Edward S.} and Rush, {A. John} and Trivedi, {Madhukar H.} and Preskorn, {Sheldon H.}",
year = "2009",
language = "English (US)",
volume = "14",
pages = "487--498",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "9",

}

TY - JOUR

T1 - Factors associated with concomitant psychotropic drug use in the treatment of major depression

T2 - A STAR*D report

AU - Shelton, Richard C.

AU - Hollon, Steve D.

AU - Wisniewski, Stephen R.

AU - Alpert, Jonathan E.

AU - Balasubramani, G. K.

AU - Friedman, Edward S.

AU - Rush, A. John

AU - Trivedi, Madhukar H.

AU - Preskorn, Sheldon H.

PY - 2009

Y1 - 2009

N2 - Introduction: Concomitant psychotropic medication (CPM) treatment is common in persons with major depression (MDD). However, relationships with patient characteristics and response to treatment are unclear. Methods: Participants with nonpsychotic MDD (N=2682) were treated with citalopram, 20-60 mg/day. Sociodemographic, clinical, and treatment outcome characteristics were compared between those using CPMs at study entry or during up to 14 weeks of citalopram treatment, and non-users. Results: About 35% of participants used a CPM. Insomnia was the predominant indication (70.3%). CPM users were more likely to be seen in primary care settings (69.3% versus 30.7%), be white, of non-Hispanic ethnicity, married, and have a higher income, private insurance, and certain comorbid disorders. CPM users had greater depressive severity, poorer physical and mental functioning, and poorer quality of life than non-users. Response and remission rates were also lower. CPM users were more likely to achieve ≥50 mg/day of citalopram, to report greater side effect intensity, and to have serious adverse events, but less likely to be intolerant of citalopram. Conclusion: CPMs are associated with greater illness burden, more Axis I comorbidities (especially anxiety disorders), and lower treatment effectiveness. This suggests that CPM use may identify a more difficult to treat population that needs more aggressive treatment.

AB - Introduction: Concomitant psychotropic medication (CPM) treatment is common in persons with major depression (MDD). However, relationships with patient characteristics and response to treatment are unclear. Methods: Participants with nonpsychotic MDD (N=2682) were treated with citalopram, 20-60 mg/day. Sociodemographic, clinical, and treatment outcome characteristics were compared between those using CPMs at study entry or during up to 14 weeks of citalopram treatment, and non-users. Results: About 35% of participants used a CPM. Insomnia was the predominant indication (70.3%). CPM users were more likely to be seen in primary care settings (69.3% versus 30.7%), be white, of non-Hispanic ethnicity, married, and have a higher income, private insurance, and certain comorbid disorders. CPM users had greater depressive severity, poorer physical and mental functioning, and poorer quality of life than non-users. Response and remission rates were also lower. CPM users were more likely to achieve ≥50 mg/day of citalopram, to report greater side effect intensity, and to have serious adverse events, but less likely to be intolerant of citalopram. Conclusion: CPMs are associated with greater illness burden, more Axis I comorbidities (especially anxiety disorders), and lower treatment effectiveness. This suggests that CPM use may identify a more difficult to treat population that needs more aggressive treatment.

UR - http://www.scopus.com/inward/record.url?scp=70849120686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70849120686&partnerID=8YFLogxK

M3 - Article

C2 - 19890231

AN - SCOPUS:70849120686

VL - 14

SP - 487

EP - 498

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 9

ER -